Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.


Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
10 2019
Historique:
received: 14 02 2019
revised: 21 05 2019
accepted: 08 07 2019
pubmed: 17 7 2019
medline: 10 6 2020
entrez: 17 7 2019
Statut: ppublish

Résumé

The oncogenic MUC1-C protein and the TWIST1 epithelial-mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the

Identifiants

pubmed: 31308076
pii: 1535-7163.MCT-19-0156
doi: 10.1158/1535-7163.MCT-19-0156
pmc: PMC6774902
mid: NIHMS1534725
doi:

Substances chimiques

MUC1 protein, human 0
Mucin-1 0
Nuclear Proteins 0
TWIST1 protein, human 0
Twist-Related Protein 1 0
Paclitaxel P88XT4IS4D

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1744-1754

Subventions

Organisme : NCI NIH HHS
ID : R01 CA097098
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166480
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA216553
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA229716
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Breast Dis. 2010;32(1-2):35-48
pubmed: 21778573
Cell Stem Cell. 2010 Jul 2;7(1):51-63
pubmed: 20621050
Mol Cancer Res. 2013 Jul;11(7):714-23
pubmed: 23538857
Sci Rep. 2017 Aug 7;7(1):7481
pubmed: 28785086
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
PLoS One. 2015 Aug 12;10(8):e0135156
pubmed: 26267657
Cancer Biol Ther. 2009 Jul;8(13):1197-203
pubmed: 19556858
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11494-11499
pubmed: 29073077
Oncogene. 2015 Oct 1;34(40):5187-97
pubmed: 25659581
Oncogene. 2014 Jun 26;33(26):3422-31
pubmed: 23912457
Breast Cancer Res. 2018 Oct 22;20(1):128
pubmed: 30348189
Trends Genet. 2017 Dec;33(12):943-959
pubmed: 28919019
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Oncogene. 2017 Feb 23;36(8):1157-1166
pubmed: 27524420
Cancer Cell. 2004 Feb;5(2):163-75
pubmed: 14998492
Clin Cancer Res. 2015 May 15;21(10):2338-47
pubmed: 25712682
Oncotarget. 2017 Jul 4;8(27):44917-44943
pubmed: 28388544
Oncogene. 2013 Feb 28;32(9):1073-81
pubmed: 22580612
Oncotarget. 2014 May 15;5(9):2622-34
pubmed: 24770886
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Springerplus. 2013 Jul 04;2(1):301
pubmed: 23888272
Cell. 2011 Jun 10;145(6):926-40
pubmed: 21663795
Cell Res. 2012 Jan;22(1):90-106
pubmed: 21876555
Signal Transduct Target Ther. 2018 May 12;3:13
pubmed: 29760958
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Oncogene. 2014 Mar 27;33(13):1680-9
pubmed: 23584475
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Cancer Res. 2018 Jan 1;78(1):205-215
pubmed: 29263152
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Oncogene. 2017 May 18;36(20):2791-2801
pubmed: 27893710
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Nat Cell Biol. 2014 Jun;16(6):488-94
pubmed: 24875735
Int J Oncol. 2012 May;40(5):1643-9
pubmed: 22200620
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925694
Oncogene. 2012 Jul 5;31(27):3223-34
pubmed: 22056872
J Biol Chem. 2012 Jun 15;287(25):20866-75
pubmed: 22544745
Cancer Res. 2009 Sep 1;69(17):7013-21
pubmed: 19706766
Cancer Lett. 2014 May 1;346(2):225-36
pubmed: 24384091
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Mol Cancer Res. 2016 Dec;14(12):1266-1276
pubmed: 27658423
Oncogene. 2016 Dec 15;35(50):6439-6445
pubmed: 27212035
J Biol Chem. 2013 Oct 25;288(43):30892-903
pubmed: 24043631
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122
pubmed: 28302417
Sci Signal. 2011 Feb 15;4(160):ra9
pubmed: 21325207
PLoS One. 2015 Aug 21;10(8):e0135851
pubmed: 26295469
Cancer Res. 2009 Jun 15;69(12):5133-41
pubmed: 19491255
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Oncogene. 2018 Apr;37(16):2079-2088
pubmed: 29379165
Cancer Res. 2009 Apr 1;69(7):2887-95
pubmed: 19276366

Auteurs

Tsuyoshi Hata (T)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Hasan Rajabi (H)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Masaaki Yamamoto (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Caining Jin (C)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Rehan Ahmad (R)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yan Zhang (Y)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Ling Kui (L)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Wei Li (W)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yota Yasumizu (Y)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Deli Hong (D)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Masaaki Miyo (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Masayuki Hiraki (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Takahiro Maeda (T)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Yozo Suzuki (Y)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Hidekazu Takahashi (H)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Mehmet Samur (M)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Donald Kufe (D)

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. donald_kufe@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH